A total of 40 patients admitted with UTI at the pediatric nephrology ward were included in the study. Exclusion criteria were: negative urine culture, no evidence of pyelonephritis on Dimercaptosuccinic acid (DMSA) scan, systemic diseases and chronic kidney disease (CKD).
Before treatment, urine and blood samples for Ghrelin were collected and stored at -20°C. In addition, U/A, U/C, urine Creatinine (Cr), CBC, ESR, CRP, BUN , Cr, BS, TG and cholesterol were measured. On the fifth day of admission, samplings for the above-mentioned tests were repeated. Other investigations were ultrasonography (US), Voiding Cystourethrography (VCUG) and DMSA scan (
4,
5). On the last day of study, urine samples were melted and Ghrelin concentration measured with human Acylated Ghrelin Elisa kit, Eurommun company China.
Ethical issues.
The study was approved by the institutional ethics committee of Shahid Beheshti University of Medical Sciences. A written informed consent was obtained from the parents of all the study participants.